The introduction of an intestinal ultrasound service is associated with significantly reduced endoscopy usage in an inflammatory bowel disease service-the SCOPELESS study [0.03%]
肠道超声检查的引入与炎症性肠病诊疗中的内窥镜使用量显著下降相关——来自SCOPELESS研究的证据
Grace S Feng,Robert D Little,Zaid Ardalan et al.
Grace S Feng et al.
Introduction: Endoscopy has been the gold standard for the assessment of inflammatory bowel disease (IBD) activity. Increasingly, intestinal ultrasound (IUS) is utilized as an alternative non-invasive disease monitoring s...
Mucocutaneous Crohn's disease without gastrointestinal symptoms: a case of oral lesions responsive to risankizumab [0.03%]
无胃肠道症状的克罗恩病伴粘膜皮肤病变一例及risankizumab治疗反应阳性
Junaid Khan,Mehak Bassi,Daniel K Daniels
Junaid Khan
Does inflammatory bowel disease play a role in cognitive decline? A systematic review [0.03%]
炎症性肠病在认知功能下降中起作用吗？系统综述
Annagiulia Motisi Bertulli,Cristina Bezzio,Silvia Marsano et al.
Annagiulia Motisi Bertulli et al.
Background & aims: Inflammatory bowel disease (IBD) has been increasingly linked to cognitive impairment (CI) and dementia, yet the underlying mechanisms driving this association remain poorly understood and population, c...
Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial [0.03%]
基于磁共振成像的简化型MaRIA评分与克罗恩病未来的手术相关，但其与回结肠镜炎症的适度关联限制了它在临床试验中的实用性：来自PROFILE试验的结果
Megha Bhandari,Mohmmed Tauseef Sharip,Nurulamin M Noor et al.
Megha Bhandari et al.
Background: Ileo-colonoscopy provides accurate assessment of mucosal inflammation in Crohn's disease. Magnetic resonance imaging (MRI) offers a non-invasive alternative. MRI-based scores such as the simplified MaRIA (sMaR...
Epigenetic biomarkers in inflammatory bowel diseases-computational challenges and opportunities [0.03%]
炎症性肠病的表观遗传生物标志物-计算挑战和机遇
Seokjun Lee,Jaesub Park,Hyun Chang Lee et al.
Seokjun Lee et al.
Inflammatory bowel diseases (IBD) remain a therapeutic challenge due to their heterogeneous nature and the absence of clinically actionable biomarkers to guide precision treatment. While multi-omics studies have advanced our understanding o...
TL1A as a therapeutic renaissance in inflammatory bowel disease: a systematic review from molecular mechanisms to clinical translation [0.03%]
从分子机制到临床转化的炎性肠病治疗中的TL1A复兴：系统综述
Raymond Fueng-Hin Liang,Cecilia Lina Pugliano,Robert Hughes et al.
Raymond Fueng-Hin Liang et al.
Background and aims: Despite major therapeutic advances, many patients with inflammatory bowel disease (IBD) continue to experience inadequate treatment response, progressive disease, and irreversible complications requir...
A de novo nonsense RELA mutation presenting as severe isolated very early-onset inflammatory bowel disease [0.03%]
由新的RELAXNP突变引起的重度孤立性极早期炎症性肠病一例报告
Elmira I Alieva,Natalya B Kuryakova,Alexander S Tertychny
Elmira I Alieva
Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis [0.03%]
全球人群中炎症性肠病表型的比较分析
Charles N Bernstein,Gilaad G Kaplan,Zoann Nugent et al.
Charles N Bernstein et al.
Background: The aim of this study was to determine if Crohn's disease (CD) and ulcerative colitis (UC) manifest similarly in different parts of the world. ...
Comparative Study
Journal of Crohn's & colitis. 2026 May 8;20(5):jjag051. DOI:10.1093/ecco-jcc/jjag051 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus [0.03%]
重新考虑炎症性肠病临床试验中洗脱期：国际共识德尔菲调查
Pauline Wils,Vipul Jairath,Bruce E Sands et al.
Pauline Wils et al.
Background & aims: Prolonged washout periods between advanced therapies and investigational drugs are commonly required in inflammatory bowel disease (IBD) randomized controlled trials (RCTs). These requirements restrict ...